Research programme: tyrosine kinase inhibitors - Onconova

Drug Profile

Research programme: tyrosine kinase inhibitors - Onconova

Alternative Names: Bcr-Abl/JAK2 inhibitors - Onconova; HER1 inhibitors - Onconova; HER2 inhibitors - Onconova; HER2-inhibitors; ON01135; ON012380; ON01370; ON044580; ON045270; ON128030; ON128060

Latest Information Update: 08 Sep 2010

Price : $50

At a glance

  • Originator Onconova Therapeutics
  • Class Benzene derivatives; Pyrimidines; Quinazolines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 08 Sep 2010 Preclinical development is ongoing in USA
  • 08 Sep 2010 Research programme: tyrosine kinase inhibitors - Onconova is available for licensing as of 08 Sep 2010. http://www.onconova.com/partneringopportunities.shtml
  • 06 Apr 2009 Research programme is still in preclinical trials for Cancer in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top